Shanghai Kechow Pharma, Inc. was established in 2014. It is a new drug R&D company integrating drug discovery, clinical development, and sales. Focused on independent R&D and scientific innovation, it is committed to addressing global unmet clinical needs. It is also committed to bridging gaps both domestically and internationally and providing high-quality new anti-cancer drugs for cancer patients worldwide.

Its self-developed targeted anti-cancer new drug, Tunlametinib (Kolupin), has completed its registered clinical trial and submitted its NDA application. In March 2024, it received new drug approval, officially entering the full-scale commercialization phase. The second new drug, HL-003 Radiotherapy Protectant, is currently undergoing Phase I clinical trials. It also has a wide range of potential market applications. In addition, Kechow Pharma has several self-developed new drug products in various stages of research and development. As a result, it has a rich product development pipeline, and its products have been granted international patents in China, the United States, Europe, and Japan. Moreover, it is in a stage of rapid growth and commercialization.

At the same time, Kechow Pharma is actively engaged in external collaborations to complement each other's strengths and jointly promote the development of China's healthcare industry for the benefit of society. In 2021, it partnered with Roche to advance research in oncology. Roche granted the marketing rights for its tumor-targeting drug Zelboraf to Kechow Pharma in China. In 2024, it will collaborate with Sinopharm to improve the accessibility of its products in China, thereby benefiting oncologists and tumor patients more promptly and extensively.

Kechow Pharma, focusing on scientific innovation, makes life better!